top of page
  • Jonathan Poyer

The Doctor Is In - Biotech in July


A conversation regarding the Therapeutics market and why it is standing out from other segments of biotech and health sciences.




Other topics covered:

  • Urogen (URGN) and its triple-digit performance

  • What is going on with SMID stocks

  • An assessment of obesity drugs and its potential impact on markets and society

5 views0 comments
bottom of page